Ditchcarbon
  • Contact
  1. Organizations
  2. Astellas
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated 19 days ago

Astellas Sustainability Profile

Company website

Astellas Pharma Inc., commonly referred to as Astellas, is a leading global pharmaceutical company headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative medicines, Astellas focuses on areas such as oncology, urology, immunology, and neuroscience. The company is renowned for its commitment to research and development, which has led to the introduction of unique therapies that address unmet medical needs. Astellas has achieved notable market recognition, consistently ranking among the top pharmaceutical firms worldwide, thanks to its dedication to improving patient outcomes and advancing healthcare solutions.

DitchCarbon Score

How does Astellas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

60

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Astellas's score of 60 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.

74%

Let us know if this data was useful to you

Astellas's reported carbon emissions

In 2024, Astellas Pharma Inc., headquartered in Japan (JP), reported total greenhouse gas emissions of approximately 1,384,000,000 kg CO2e. This includes 52,212,000 kg CO2e from Scope 1, 55,621,000 kg CO2e from Scope 2, and a significant 1,276,323,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its emissions, aiming for a 63% reduction in Scope 1 and 2 emissions by FY2030, based on a 2015 baseline, and a 37.5% reduction in Scope 3 emissions by the same year. Astellas has committed to achieving net-zero greenhouse gas emissions across all scopes by 2050. This long-term goal aligns with the Paris Agreement and reflects the company's dedication to sustainable practices. The targets have been validated by the Science Based Targets initiative (SBTi), ensuring they are consistent with the latest climate science. In 2023, Astellas reported total emissions of approximately 1,121,350,000 kg CO2e globally, with Scope 1 emissions at 59,203,000 kg CO2e, Scope 2 at 63,047,000 kg CO2e, and Scope 3 at 1,121,350,000 kg CO2e. The company continues to monitor and report its emissions transparently, demonstrating a commitment to environmental responsibility and climate action.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

200520112012201320142015201620172018201920202021202220232024
Scope 1
108,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Astellas's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Astellas's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Astellas's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Astellas is in JP, which has a low grid carbon intensity relative to other regions.

Astellas's Scope 3 Categories Breakdown

Astellas's Scope 3 emissions, which increased by 14% last year and decreased by approximately 7% since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 85% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
85%
Capital Goods
7%
Business Travel
3%
Fuel and Energy Related Activities
2%
Upstream Transportation & Distribution
2%
Downstream Transportation & Distribution
1%
Downstream Leased Assets
<1%
Employee Commuting
<1%
Waste Generated in Operations
<1%
End-of-Life Treatment of Sold Products
<1%

Astellas's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Astellas has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Astellas's Emissions with Industry Peers

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Asahi Kasei Pharma Corporation

JP
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Best Medical International, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Genentech

US
•
Pharmaceutical Preparation Manufacturing
Updated about 11 hours ago

Meda AB

SE
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Frequently Asked Questions

Common questions about Astellas's sustainability data and climate commitments

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251118.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy